Knight Therapeutics (OTCMKTS:KHTRF) Trading 1% Higher – Here’s Why

Knight Therapeutics Inc. (OTCMKTS:KHTRF) shot up 1% during trading on Thursday . The company traded as high as $6.05 and last traded at $6.05. 3,000 shares were traded during mid-day trading, a decline of 59% from the average session volume of 7,284 shares. The stock had previously closed at $5.99.

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Knight Therapeutics in a research note on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, Knight Therapeutics presently has an average rating of “Buy”.

Knight Therapeutics Stock Performance

The company’s 50 day moving average price is $5.72 and its 200 day moving average price is $4.86.

Knight Therapeutics Company Profile

Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.

Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.